Anti-CD16 x IL-15 x anti-CD33 TriKE played an anti-tumor role through eliciting NK cell functions in mouse models of tumors (Vallera et al., 2016; Vallera et al., 2020), and its efficacy was reported in a terminated clinical trial (NCT03214666). The gene discussed is IL15; the disease is neoplasm.